160 related articles for article (PubMed ID: 37812295)
21. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma.
Sposito C; Ratti F; Cucchetti A; Ardito F; Ruzzenente A; Di Sandro S; Maspero M; Ercolani G; Di Benedetto F; Guglielmi A; Giuliante F; Aldrighetti L; Mazzaferro V
J Hepatol; 2023 Feb; 78(2):356-363. PubMed ID: 36328332
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
23. Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres.
Kumar P; Mhaskar R; Kim R; Anaya D; Frakes J; Hoffe S; Choi J; Kis B
J Clin Exp Hepatol; 2022; 12(5):1259-1263. PubMed ID: 36157145
[TBL] [Abstract][Full Text] [Related]
24. Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by
Schaarschmidt BM; Kloeckner R; Dertnig T; Demircioglu A; Müller L; Auer TA; Santos DPD; Steinle V; Miederer M; Gebauer B; Radunz S; Kasper S; Weber M; Theysohn J
J Nucl Med; 2023 Apr; 64(4):529-535. PubMed ID: 36328487
[TBL] [Abstract][Full Text] [Related]
25. Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial.
Chan SL; Chotipanich C; Choo SP; Kwang SW; Mo F; Worakitsitisatorn A; Tai D; Sundar R; Ng DCE; Loke KSH; Li L; Ng KKC; Peng YW; Yu SC
Liver Cancer; 2022 Sep; 11(5):451-459. PubMed ID: 36158588
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.
Shah RM; Sheikh S; Shah J; Vivian E; Mejia A; Shahin I; Mantry PS
J Gastrointest Oncol; 2021 Aug; 12(4):1718-1731. PubMed ID: 34532122
[TBL] [Abstract][Full Text] [Related]
27. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
[TBL] [Abstract][Full Text] [Related]
28. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.
Al-Adra DP; Gill RS; Axford SJ; Shi X; Kneteman N; Liau SS
Eur J Surg Oncol; 2015 Jan; 41(1):120-7. PubMed ID: 25449754
[TBL] [Abstract][Full Text] [Related]
29. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma.
Paz-Fumagalli R; Core J; Padula C; Montazeri S; McKinney J; Frey G; Devcic Z; Lewis A; Ritchie C; Mody K; Krishnan S; Toskich B
Oncotarget; 2021 Sep; 12(20):2075-2088. PubMed ID: 34611481
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial.
Garin E; Tselikas L; Guiu B; Chalaye J; Rolland Y; de Baere T; Assenat E; Tacher V; Palard X; Déandreis D; Mariano-Goulart D; Amaddeo G; Boudjema K; Hollebecque A; Meerun MA; Regnault H; Vibert E; Campillo-Gimenez B; Edeline J
J Nucl Med; 2024 Feb; 65(2):264-269. PubMed ID: 38212068
[TBL] [Abstract][Full Text] [Related]
31. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
32. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma.
Riby D; Mazzotta AD; Bergeat D; Verdure L; Sulpice L; Bourien H; Lièvre A; Rolland Y; Garin E; Boudjema K; Edeline J
Ann Surg Oncol; 2020 Oct; 27(10):3729-3737. PubMed ID: 32472411
[TBL] [Abstract][Full Text] [Related]
33. Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Yousaf A; Kim JU; Eliahoo J; Taylor-Robinson SD; Khan SA
J Clin Exp Hepatol; 2019; 9(6):740-748. PubMed ID: 31889756
[TBL] [Abstract][Full Text] [Related]
34. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review.
Belkouz A; Nooijen LE; Riady H; Franken LC; van Oijen MGH; Punt CJA; Erdmann JI; Klümpen HJ
Cancer Treat Rev; 2020 Dec; 91():102110. PubMed ID: 33075684
[TBL] [Abstract][Full Text] [Related]
36. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
[TBL] [Abstract][Full Text] [Related]
37. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
38. Foreign body granuloma reaction following SIRT mimicking peritoneal metastases: a word of caution.
Willems E; Smet B; Dedeurwaerdere F; D'Hondt M
Acta Chir Belg; 2020 Feb; 120(1):47-49. PubMed ID: 30092710
[TBL] [Abstract][Full Text] [Related]
39. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
[TBL] [Abstract][Full Text] [Related]
40. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.
Cheng B; Villalobos A; Sethi I; Wagstaff W; Galt J; Brandon D; Schuster DM; Bercu Z; Majdalany B; Kokabi N
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1194-1203. PubMed ID: 33890170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
